JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 427-428

  Sène, Damien ^a,b   Elalamy, Ismail ^a,b   Ancri, Annick ^a,b   Cacoub, Patrice ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III DEFICIENCY; ARTERY THROMBOSIS; BUDD CHIARI SYNDROME; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; LETTER; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RECURRENT DISEASE; VEIN THROMBOSIS;

ADULT; AGED; ARTERIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POINT MUTATION; RECURRENCE; RISK FACTORS; VEINS; VENOUS THROMBOSIS;

EID: 45849130208     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.12.008     Document Type: Letter

References (5)

1. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 5 (1998) 327-331
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. De Stefano V., Fiorini A., Rossi E., Za T., Farina G., Chiusolo P., et al. Prevalence of the JAK2(V617F) mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5 4 (2007) 708-716
4. Colaizzo D., Amitrano L., Tiscia G.L., Scenna G., Grandone E., Guardascione M.A., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5 (2007) 55-61
5. James C., Delhommeau F., Marzac C., Teyssandier I., Couedic J.P., Giraudier S., et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20 (2006) 350-353